BIB holdings
ProShares Ultra Nasdaq Biotechnology
Positions
267 stored of 267 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Total Return Swap | Not reported | Not reported | 7.355% | $5.4M | Equity derivatives | Other | United States | USD |
| 2 | ProShares GENIUS Money Market ETF | US74350P6916 | 74350P691 | 6.797% | $5.0M | Other | Registered fund | United States | USD |
| 3 | Gilead Sciences, Inc. | US3755581036 | 375558103 | 4.662% | $3.4M | Equity (common) | Corporate | United States | USD |
| 4 | Vertex Pharmaceuticals, Inc. | US92532F1003 | 92532F100 | 4.653% | $3.4M | Equity (common) | Corporate | United States | USD |
| 5 | Amgen, Inc. | US0311621009 | 031162100 | 4.483% | $3.3M | Equity (common) | Corporate | United States | USD |
| 6 | Total Return Swap | Not reported | Not reported | 3.942% | $2.9M | Equity derivatives | Other | United States | USD |
| 7 | Total Return Swap | Not reported | Not reported | 3.263% | $2.4M | Equity derivatives | Other | United States | USD |
| 8 | Regeneron Pharmaceuticals, Inc. | US75886F1075 | 75886F107 | 3.205% | $2.4M | Equity (common) | Corporate | United States | USD |
| 9 | Total Return Swap | Not reported | Not reported | 2.621% | $1.9M | Equity derivatives | Other | United States | USD |
| 10 | Total Return Swap | Not reported | Not reported | -2.356% | -$1.7M | Equity derivatives | Other | United States | USD |
| 11 | Alnylam Pharmaceuticals, Inc. | US02043Q1076 | 02043Q107 | 2.011% | $1.5M | Equity (common) | Corporate | United States | USD |
| 12 | Revolution Medicines, Inc. | US76155X1000 | 76155X100 | 1.566% | $1.2M | Equity (common) | Corporate | United States | USD |
| 13 | Biogen, Inc. | US09062X1037 | 09062X103 | 1.444% | $1.1M | Equity (common) | Corporate | United States | USD |
| 14 | Repurchase Agreement | Not reported | Not reported | 1.283% | $945K | Repurchase agreements | Corporate | United States | USD |
| 15 | Illumina, Inc. | US4523271090 | 452327109 | 1.251% | $921K | Equity (common) | Corporate | United States | USD |
| 16 | United Therapeutics Corp. | US91307C1027 | 91307C102 | 1.225% | $902K | Equity (common) | Corporate | United States | USD |
| 17 | Royalty Pharma plc Royalty Pharma plc, Class A | GB00BMVP7Y09 | Not reported | 1.199% | $883K | Equity (common) | Corporate | United Kingdom | USD |
| 18 | Argenx SE | US04016X1019 | 04016X101 | 1.192% | $878K | Equity (common) | Corporate | Netherlands | USD |
| 19 | Total Return Swap | Not reported | Not reported | 1.183% | $871K | Equity derivatives | Other | United States | USD |
| 20 | Insmed, Inc. | US4576693075 | 457669307 | 1.157% | $852K | Equity (common) | Corporate | United States | USD |
| 21 | Roivant Sciences Ltd. | BMG762791017 | Not reported | 1.077% | $794K | Equity (common) | Corporate | Bermuda | USD |
| 22 | Incyte Corp. | US45337C1027 | 45337C102 | 0.967% | $712K | Equity (common) | Corporate | United States | USD |
| 23 | Viatris, Inc. | US92556V1061 | 92556V106 | 0.940% | $692K | Equity (common) | Corporate | United States | USD |
| 24 | Moderna, Inc. | US60770K1079 | 60770K107 | 0.935% | $689K | Equity (common) | Corporate | United States | USD |
| 25 | Guardant Health, Inc. | US40131M1099 | 40131M109 | 0.854% | $629K | Equity (common) | Corporate | United States | USD |
| 26 | INVESCO GOVT AND AGCY LEX INVESCO GOVERNMENT & AGENCY PORTFOLIO OPEN-END FUND USD | Not reported | 825252885 | 0.812% | $598K | Short-term investment vehicles (cash funds) | Registered fund | United States | USD |
| 27 | Repurchase Agreement | Not reported | Not reported | 0.807% | $594K | Repurchase agreements | Corporate | United States | USD |
| 28 | Neurocrine Biosciences, Inc. | US64125C1099 | 64125C109 | 0.798% | $588K | Equity (common) | Corporate | United States | USD |
| 29 | Jazz Pharmaceuticals plc | IE00B4Q5ZN47 | Not reported | 0.730% | $538K | Equity (common) | Corporate | Ireland | USD |
| 30 | Ascendis Pharma A/S | DK0060615755 | Not reported | 0.693% | $510K | Equity (common) | Corporate | Denmark | USD |
| 31 | Summit Therapeutics, Inc. | US86627T1088 | 86627T108 | 0.683% | $503K | Equity (common) | Corporate | United States | USD |
| 32 | Exelixis, Inc. | US30161Q1040 | 30161Q104 | 0.658% | $485K | Equity (common) | Corporate | United States | USD |
| 33 | Bridgebio Pharma, Inc. | US10806X1028 | 10806X102 | 0.645% | $475K | Equity (common) | Corporate | United States | USD |
| 34 | Medpace Holdings, Inc. | US58506Q1094 | 58506Q109 | 0.638% | $470K | Equity (common) | Corporate | United States | USD |
| 35 | Ionis Pharmaceuticals, Inc. | US4622221004 | 462222100 | 0.635% | $467K | Equity (common) | Corporate | United States | USD |
| 36 | Repurchase Agreement | Not reported | Not reported | 0.605% | $446K | Repurchase agreements | Corporate | United States | USD |
| 37 | Axsome Therapeutics, Inc. | US05464T1043 | 05464T104 | 0.602% | $443K | Equity (common) | Corporate | United States | USD |
| 38 | Madrigal Pharmaceuticals, Inc. | US5588681057 | 558868105 | 0.572% | $421K | Equity (common) | Corporate | United States | USD |
| 39 | BioMarin Pharmaceutical, Inc. | US09061G1013 | 09061G101 | 0.553% | $407K | Equity (common) | Corporate | United States | USD |
| 40 | BioNTech SE | US09075V1026 | 09075V102 | 0.549% | $404K | Equity (common) | Corporate | Germany | USD |
| 41 | Arrowhead Pharmaceuticals, Inc. | US04280A1007 | 04280A100 | 0.548% | $403K | Equity (common) | Corporate | United States | USD |
| 42 | Sanofi SA | US80105N1054 | 80105N105 | 0.536% | $395K | Equity (common) | Corporate | France | USD |
| 43 | Praxis Precision Medicines, Inc. | US74006W2070 | 74006W207 | 0.489% | $360K | Equity (common) | Corporate | United States | USD |
| 44 | Cytokinetics, Inc. | US23282W6057 | 23282W605 | 0.475% | $349K | Equity (common) | Corporate | United States | USD |
| 45 | BeOne Medicines Ltd. | US07725L1026 | 07725L102 | 0.462% | $340K | Equity (common) | Corporate | Switzerland | USD |
| 46 | Krystal Biotech, Inc. | US5011471027 | 501147102 | 0.453% | $334K | Equity (common) | Corporate | United States | USD |
| 47 | Repurchase Agreement | Not reported | Not reported | 0.444% | $327K | Repurchase agreements | Corporate | United States | USD |
| 48 | Tempus AI, Inc. Tempus AI, Inc., Class A | US88023B1035 | 88023B103 | 0.440% | $324K | Equity (common) | Corporate | United States | USD |
| 49 | Abivax SA | US00370M1036 | 00370M103 | 0.409% | $301K | Equity (common) | Corporate | France | USD |
| 50 | Nuvalent, Inc. Nuvalent, Inc., Class A | US6707031075 | 670703107 | 0.405% | $299K | Equity (common) | Corporate | United States | USD |
| 51 | Halozyme Therapeutics, Inc. | US40637H1095 | 40637H109 | 0.394% | $290K | Equity (common) | Corporate | United States | USD |
| 52 | ImmunityBio, Inc. | US45256X1037 | 45256X103 | 0.388% | $286K | Equity (common) | Corporate | United States | USD |
| 53 | Vaxcyte, Inc. | US92243G1085 | 92243G108 | 0.371% | $273K | Equity (common) | Corporate | United States | USD |
| 54 | Alkermes plc | IE00B56GVS15 | Not reported | 0.353% | $260K | Equity (common) | Corporate | Ireland | USD |
| 55 | Immunovant, Inc. | US45258J1025 | 45258J102 | 0.340% | $251K | Equity (common) | Corporate | United States | USD |
| 56 | Kymera Therapeutics, Inc. | US5015751044 | 501575104 | 0.334% | $246K | Equity (common) | Corporate | United States | USD |
| 57 | Protagonist Therapeutics, Inc. | US74366E1029 | 74366E102 | 0.319% | $235K | Equity (common) | Corporate | United States | USD |
| 58 | Mirum Pharmaceuticals, Inc. | US6047491013 | 604749101 | 0.307% | $226K | Equity (common) | Corporate | United States | USD |
| 59 | PTC Therapeutics, Inc. | US69366J2006 | 69366J200 | 0.307% | $226K | Equity (common) | Corporate | United States | USD |
| 60 | Rhythm Pharmaceuticals, Inc. | US76243J1051 | 76243J105 | 0.303% | $223K | Equity (common) | Corporate | United States | USD |
| 61 | Spyre Therapeutics, Inc. | US00773J2024 | 00773J202 | 0.290% | $214K | Equity (common) | Corporate | United States | USD |
| 62 | Cogent Biosciences, Inc. | US19240Q2012 | 19240Q201 | 0.285% | $210K | Equity (common) | Corporate | United States | USD |
| 63 | CRISPR Therapeutics AG | CH0334081137 | Not reported | 0.271% | $199K | Equity (common) | Corporate | Switzerland | USD |
| 64 | CG oncology, Inc. | US1569441009 | 156944100 | 0.264% | $195K | Equity (common) | Corporate | United States | USD |
| 65 | Scholar Rock Holding Corp. | US80706P1030 | 80706P103 | 0.253% | $186K | Equity (common) | Corporate | United States | USD |
| 66 | Centessa Pharmaceuticals plc | US1523091007 | 152309100 | 0.239% | $176K | Equity (common) | Corporate | United Kingdom | USD |
| 67 | Caris Life Sciences, Inc. | US1421521071 | 142152107 | 0.237% | $174K | Equity (common) | Corporate | United States | USD |
| 68 | Ligand Pharmaceuticals, Inc. | US53220K5048 | 53220K504 | 0.232% | $171K | Equity (common) | Corporate | United States | USD |
| 69 | Xenon Pharmaceuticals, Inc. | CA98420N1050 | 98420N105 | 0.228% | $168K | Equity (common) | Corporate | Canada | USD |
| 70 | Apogee Therapeutics, Inc. | US03770N1019 | 03770N101 | 0.226% | $167K | Equity (common) | Corporate | United States | USD |
| 71 | Indivior Pharmaceuticals, Inc. | US45579U1097 | 45579U109 | 0.226% | $167K | Equity (common) | Corporate | United States | USD |
| 72 | Travere Therapeutics, Inc. | US89422G1076 | 89422G107 | 0.218% | $161K | Equity (common) | Corporate | United States | USD |
| 73 | Amneal Pharmaceuticals, Inc. | US03168L1052 | 03168L105 | 0.208% | $153K | Equity (common) | Corporate | United States | USD |
| 74 | Twist Bioscience Corp. | US90184D1000 | 90184D100 | 0.206% | $152K | Equity (common) | Corporate | United States | USD |
| 75 | Erasca, Inc. | US29479A1088 | 29479A108 | 0.200% | $147K | Equity (common) | Corporate | United States | USD |
| 76 | Newamsterdam Pharma Co. NV | NL00150012L7 | Not reported | 0.194% | $143K | Equity (common) | Corporate | Netherlands | USD |
| 77 | Crinetics Pharmaceuticals, Inc. | US22663K1079 | 22663K107 | 0.187% | $138K | Equity (common) | Corporate | United States | USD |
| 78 | ACADIA Pharmaceuticals, Inc. | US0042251084 | 004225108 | 0.185% | $137K | Equity (common) | Corporate | United States | USD |
| 79 | Veracyte, Inc. | US92337F1075 | 92337F107 | 0.185% | $136K | Equity (common) | Corporate | United States | USD |
| 80 | Edgewise Therapeutics, Inc. | US28036F1057 | 28036F105 | 0.184% | $135K | Equity (common) | Corporate | United States | USD |
| 81 | Beam Therapeutics, Inc. | US07373V1052 | 07373V105 | 0.168% | $124K | Equity (common) | Corporate | United States | USD |
| 82 | Denali Therapeutics, Inc. | US24823R1059 | 24823R105 | 0.167% | $123K | Equity (common) | Corporate | United States | USD |
| 83 | 10X Genomics, Inc. 10X Genomics, Inc., Class A | US88025U1097 | 88025U109 | 0.167% | $123K | Equity (common) | Corporate | United States | USD |
| 84 | Dyne Therapeutics, Inc. | US26818M1080 | 26818M108 | 0.160% | $118K | Equity (common) | Corporate | United States | USD |
| 85 | Structure Therapeutics, Inc. | US86366E1064 | 86366E106 | 0.154% | $113K | Equity (common) | Corporate | Cayman Islands | USD |
| 86 | Tango Therapeutics, Inc. | US87583X1090 | 87583X109 | 0.149% | $109K | Equity (common) | Corporate | United States | USD |
| 87 | Oruka Therapeutics, Inc. | US6876041087 | 687604108 | 0.142% | $105K | Equity (common) | Corporate | United States | USD |
| 88 | GRAIL, Inc. | US3847471014 | 384747101 | 0.140% | $103K | Equity (common) | Corporate | United States | USD |
| 89 | Alumis, Inc. | US0223071020 | 022307102 | 0.137% | $101K | Equity (common) | Corporate | United States | USD |
| 90 | Arcutis Biotherapeutics, Inc. | US03969K1088 | 03969K108 | 0.134% | $98K | Equity (common) | Corporate | United States | USD |
| 91 | Disc Medicine, Inc. | US2546041011 | 254604101 | 0.133% | $98K | Equity (common) | Corporate | United States | USD |
| 92 | Supernus Pharmaceuticals, Inc. | US8684591089 | 868459108 | 0.133% | $98K | Equity (common) | Corporate | United States | USD |
| 93 | Ideaya Biosciences, Inc. | US45166A1025 | 45166A102 | 0.130% | $96K | Equity (common) | Corporate | United States | USD |
| 94 | Vera Therapeutics, Inc. Vera Therapeutics, Inc., Class A | US92337R1014 | 92337R101 | 0.127% | $94K | Equity (common) | Corporate | United States | USD |
| 95 | Tarsus Pharmaceuticals, Inc. | US87650L1035 | 87650L103 | 0.127% | $93K | Equity (common) | Corporate | United States | USD |
| 96 | Relay Therapeutics, Inc. | US75943R1023 | 75943R102 | 0.126% | $93K | Equity (common) | Corporate | United States | USD |
| 97 | Mineralys Therapeutics, Inc. | US6031701013 | 603170101 | 0.125% | $92K | Equity (common) | Corporate | United States | USD |
| 98 | Definium Therapeutics, Inc. | CA24477V1058 | 24477V105 | 0.121% | $89K | Equity (common) | Corporate | Canada | USD |
| 99 | Enliven Therapeutics, Inc. | US29337E1029 | 29337E102 | 0.118% | $87K | Equity (common) | Corporate | United States | USD |
| 100 | Adaptive Biotechnologies Corp. | US00650F1093 | 00650F109 | 0.117% | $86K | Equity (common) | Corporate | United States | USD |